Medical Device Unicorn Shoulder Innovations Files for IPO, Aiming to Raise $100 Million

July 24, 2025, Innovative Medical Technology EnterpriseShoulder InnovationsSubmit an IPO prospectus to the U.S. Securities and Exchange Commission (SEC) for a planned listing on the Nasdaq under the stock code "SHLD".The fundraising size is tentatively set at 100 million US dollars (approximately 700 million RMB).This IPO will provide capital support for the company to expand its product line and accelerate the integration of AI with the surgical ecosystem, while also bringing this technology approach, focused on solving the clinical challenge of "glenoid loosening," into a broader market spotlight.

# Financial Performance and Fundraising Use: Maintaining High Growth, Focusing on Product Expansion

According to the prospectus disclosure,Shoulder Innovations Achieved Revenue of $34.57 Million in the 12 Months Ended March 31, 2025, a Year-over-Year Increase of 64.07%.Sales of the same-period implant system jumped from 559 units in the previous fiscal year to 1,443 units, with average revenue per case exceeding $20,000, reflecting strong premium pricing power in its business model and product portfolio.

In terms of gross margin, the company maintains above 80%, butNet loss reached $15.17 million, mainly due to R&D investment and sales network construction. In terms of the use of proceeds, the company plans to mainly use the IPO funds for three major directions:

• Launch revision systems and fracture-specific implants to expand surgical coverage;

• Strengthen the development of AI tools and their integration with surgical navigation systems;

• Expand the sales team and overseas market access, including EU CE certification and Asia-Pacific market layout.

This means that Shoulder Innovations will expand to more disease types and market scenarios based on its existing glenoid technology platform.

From the first round of $1.6 million financing completed in 2017 to the $40 million convertible bond financing completed just before submitting the IPO application in July 2025, Shoulder Innovations has cumulatively raised nearly $190 million in eight years.

The Series E financing completed in March 2025 and the subsequent $40 million convertible bond exclusively invested by Fidelity Management in July constituted a critical accelerator before the company's IPO.

Compared with early-stage financing, which focused more on product development and initial sales, this round of funding will mainly be used to consolidate the market coverage of existing products, continuously optimize AI software capabilities, and provide reserve resources for exploring international markets.

# Market Prospects and Competitive Landscape

From the overall perspective of the industry, the global shoulder arthroplasty market continues to expand against the backdrop of an aging population and an increase in sports injuries.It is expected that by 2030, the market size will exceed 5 billion US dollars, with an annual compound growth rate of over 7%.Among them, anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (rTSA) collectively dominate.

In this high-growth track, the direct competitors faced by Shoulder Innovations include:

• Zimmer Biomet: Comprehensive under its umbrella^®And the Signature ONE system extensively covers different surgical procedures;

• Stryker: Differentiated pathways built with the Blueprint™ 3D Preoperative Planning Platform and Versa-Dial™ series;

• DePuy Synthes (Johnson & Johnson): The INHANCE™ system emphasizes rapid switching and operator convenience.

By contrast, Shoulder Innovations' InSet™ system forms a closed-loop solution with "embedded structure + instrument simplification + AI navigation," focusing on the two core clinical pain points of postoperative stability and surgical efficiency, demonstrating potential to break through in the trend towards outpatient and streamlined procedures.

Moreover, the company's team has profound expertise in the shoulder joint field. Its core members have led the development of the world’s first modular shoulder system, reverse shoulder system, and stemless shoulder system, boasting extensive experience in implant design and patents. To date, the company has obtained over 40 related patents, covering key areas such as glenoid structure, stem design, porous coating conversion systems, and more, establishing a clear technological moat.

# Starting from glenoid loosening: InSet™ system forms a technical closed loop

Shoulder Innovations, founded in 2009 and headquartered in Michigan, has focused on the most common cause of failure in total shoulder arthroplasty since the inception of its core product, the InSet™ Shoulder Arthroplasty System —Loosening of the glenoid implant.

Compared to traditional installation methods that place the implant on the bone surface (such as surface-adhered or pegged fixation),The InSet™ system features an embedded-in-bone design, significantly reducing micromotion of the implant (commonly known as the "seesaw effect")., improve postoperative stability and extend service life. Test data shows that micromotion is reduced by up to 87%, addressing the issue at its source.Post-inflammatory, bone resorption, and implant dislocation risks.

Not only that, the company also launchedInSet™ PLUS Model，Supports angle adjustment of 5° and 10°, combined with eccentric reaming technology to address complex anatomical challenges. Meanwhile, the InSet™ Reverse product line is designed for patients with rotator cuff injuries, integrating the structural advantages of inlay and onlay systems to balance stability, bone preservation, and range of motion, forming a comprehensive product matrix for multiple indications.

In terms of intraoperative efficiency, Shoulder Innovations proposes the "Power of One™" concept, adopting a unified dual-tray instrument system that allows all operations required for anatomical and reverse shoulder arthroplasty to be completed through a single system. This design significantly reduces the types and quantity of surgical instruments, simplifies the intraoperative process, and lowers sterilization and management costs, aligning with the trend of outpatient surgery centers (ASC) promoted by U.S. Medicare.

Data shows,In the past two years, the InSet™ system has completed over 1,200 replacement surgeries, using only 30 sets of standard instruments, covering hospitals in many parts of China.This "implant-plus-device system" integrated model has created a barrier for Shoulder Innovations in terms of efficiency and cost control.

# AI Planning Platform ProVoyance: Enhancing Preoperative Precision Decision-Making

Shoulder Innovations' layout in the AI direction is also advancing simultaneously. ProVoyance™, the company's surgical planning software, has received FDA approval. It automatically constructs 3D shoulder joint models based on CT data, supports impingement-free ROM assessment, and can simulate postoperative outcomes of different implant combinations.

ProVoyance achieves personalized implant positioning, angle, and depth selection through virtual planning, especially providing higher-dimensional reference for surgeons in patients with bone defects and anatomical variations. Meanwhile, the platform is deeply integrated with the InSet™ system, capable of outputting surgical navigation assistance data based on actual implant parameters, further enhancing intraoperative stability and precision.

This gives Shoulder Innovations a competitive advantage that extends beyond the implant itself, forming a complete chain that includes preoperative assessment, intraoperative implementation, and postoperative recovery, laying the foundation for building a technological ecosystem.

# Conclusion

Shoulder Innovations has established a solution centered on "Simplified Procedures + Stable Structure + AI Planning" for traditional shoulder arthroplasty through the InSet™ system and ProVoyance platform, demonstrating significant strategic alignment particularly in the context of trends such as cost control, minimally invasive outpatient procedures, and precise preoperative design.

In the future, with the advancement of the revision system, fracture product line, and international market layout, the company is expected to further strengthen its technical closed loop and increase market penetration. If it can leverage the IPO opportunity to gain stronger capital support, Shoulder Innovations has the potential to grow from a "high-growth implant company" into an innovative orthopedic company with a complete platform architecture.